THE BLOOD FACTOR
-
Hemophilia A gene therapy approved in Europe but possibly delayed in the U.S.
Last August, the European Medicines Agency (EMA) granted conditional marketing authorization to BioMarin’s Roctavian (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A...
-
CHS strongly supports CBS’ plasma initiative
Montreal, September 7, 2022 – “The Canadian Hemophilia Society (CHS) strongly supports Canadian Blood Services’ plans to work with a leading company in the plasma...
-
No change to factor IX product mix in Quebec
Montreal, August 15, 2022 – On July 15, Héma-Québec announced the results of the recombinant factor IX tender for the period from October 1, 2022...
-
Blood donation: dispelling a myth
Eligibility for blood donation in Canada is constantly evolving. For many years, the sexual partners of people with bleeding disorders were deferred from blood donation....
-
Update on products in the pipeline
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates, inhibitor...